Added to YB: 2025-05-05
Pitch date: 2025-04-30
PFE [neutral]
Pfizer Inc.
+18.56%
current return
Author Info
LongYield content includes: in-depth company/industry analysis (Business Deepdives), summaries of earnings calls (Earnings Calls Summaries), and analysis of US/European economies (Economic Reports). Sign up for the newsletter.
Company Info
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.
Market Cap
$155.6B
Pitch Price
$22.66
Price Target
28.00 (+4%)
Dividend
6.28%
EV/EBITDA
7.90
P/E
20.13
EV/Sales
3.24
Sector
Pharmaceuticals
Category
turnaround
Pfizer's Q1 2025 Triumph: EPS Beats, Bold Cost Savings, and Oncology Breakthroughs
PFE (earnings update): Q1 rev $13.72B (-8% YoY), missed consensus. Adj EPS $0.92 (+12%) beat on cost cuts. COVID product declines offset by growth in Vyndaqel (+33%), Comirnaty (+62%). $5.7B cost savings by 2027. Pipeline progress in oncology despite danuglipron discontinuation. Haleon stake sold for $3.3B. Potential tariff risks not in 2025 guidance.
Read full article (5 min)